P112 Non-invasive ventilation in motor neurone disease, an audit of a tertiary centers practice

BACKGROUND: MND is a progressive neurodegenerative disorder with significant morbidity and mortality. The prevalence in Australasia is the second highest in the world with 12.9 cases per 100 000. Impairment of respiratory function contributes to and correlates with QOL. Respiratory complications are the most common causes of death. NIV improves or maintains QOL in patients with MND and prolongs median survival by up to 205 days in patients with normal to moderately impaired bulbar function. NICE guidelines recommend considering a trial NIV in those with symptoms, signs or evidence of impaired respiratory muscle strength. METHODS: A single centre, retrospective database and chart review of all incident and prevalent cases with two clinical interactions at the Princess Alexandra Hospital MND service between 2013-2021 was conducted. The primary aim was to determine the proportion of patients who trialed NIV. Secondary outcomes include: concordance with NICE Guidelines regarding NIV commencement, proportion of patients treated with riluzole and received PEG. Survival will be estimated by constructing Kaplan-Meier curves for those established on NIV compared with those that were not. PROGRESS TO DATE: A total of 211 patients were included in analysis. 62.1% males, 37.9 % female, mean age at diagnosis 62.8 years. Limb phenotype was most common (52.5%) followed by bulbar phenotype (35.9%). 36.5% of the cohort trialed NIV. Further analysis to follow. INTENDED OUTCOME AND IMPACT: The outcomes will be compared with those published in the literature facilitating benchmarking of the service and identification of facets of patient care that can be improved.